Genetically Engineered Neural Progenitor Cells for Spinal Cord Injury Repair

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for traumatic spinal cord injuries are ineffective due to limited regenerative potential of adult mammalian central nervous system neurons and a hostile injury environment that hampers the survival and differentiation of grafted neural progenitor cells, with glial scars creating barriers to axonal regeneration.

Innovation Solution

Genetically engineered neural progenitor cells with upregulated sonic hedgehog (SHH) signaling pathway, achieved by suppressing the negative regulator SUFU, are administered directly to the lesion site, enhancing survival, differentiation, and modulating the host environment to reduce glial scar barriers, combined with physical therapy for improved functional recovery.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If neural progenitor cells are grafted into the injury site, then functional recovery is improved, but the hostile injury environment causes graft differentiation into astrocytes instead of neurons

Engineering Contradiction:

Improveneuronal differentiation of graftsVSAvoidhostile injury environment

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary anti-action by pre-treating neural progenitor cells with genetic modification (overexpression of Bcl-2 and Ngn2) before grafting. This preparatory intervention equips the cells with resistance to the hostile injury environment and pre-programmed neuronal differentiation potential, countering the harmful astrocytic differentiation tendency before it occurs in the injury site

Inventive Principle:

Principle #9Preliminary anti-action

Solution Approach 2:

The patent uses dual genetic factors as intermediaries: Bcl-2 acts as a mediator to protect cells from apoptosis and environmental stress, while Ngn2 serves as a molecular mediator that drives neuronal differentiation. These intermediary molecules transmit the therapeutic effect from the grafted cells to the injury environment, overcoming the hostile conditions

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If neural progenitor cells are grafted into the injury site, then functional recovery is improved, but the pro-longed maturation process limits therapeutic effectiveness

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidmaturation process duration

Core Design Contradiction:

ProductivityVSLoss of time

Solution Approach 1:

The patent implements preliminary action by genetically pre-programming the neural progenitor cells with Ngn2 overexpression before transplantation. This preliminary genetic intervention initiates the neuronal differentiation program in advance, allowing cells to begin maturing into neurons immediately upon grafting rather than requiring prolonged in-vivo maturation time

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent applies parameter changes by modifying the genetic parameters of neural progenitor cells through transgenic manipulation. By altering the expression levels of key genes (Bcl-2 and Ngn2), the patent changes the cellular differentiation trajectory and maturation rate parameters, accelerating therapeutic effectiveness

Inventive Principle:

Principle #35Parameter changes

3Reliability

If glial scar forms after injury, then protective barrier is created, but it prevents regenerated axons from penetrating and projecting across the lesion site

Engineering Contradiction:

Improveprotective barrier functionVSAvoidaxonal regeneration

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent converts the harmful effect of glial scar formation into a beneficial outcome by using the same injury-induced environment to activate the Bcl-2 protective pathway in grafted cells. The hostile conditions that normally cause cell death and scarring are transformed into stimuli that enhance graft survival and promote axonal regeneration through the genetically engineered protective mechanisms

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20250101377A1Methods and compositions of treating spinal cord injuries

Publication Date: 2025.03.27 CITY UNIVERSITY OF HONG KONG

AI summary

A method for treating spinal cord injuries involves the administration of a genetically modified neural progenitor cell (NPC). This genetically engineered NPC is designed to exhibit an enhanced sonic hedgehog (SHH) signaling pathway. This method aims to provide a therapeutic strategy for addressing spinal cord injuries by leveraging the augmented SHH signaling pathway in the administered cells.